CHF5633

a synthetic pulmonary surfactant consisting of SP-B analog (derived from 8–25 and 63–78 portions of SP-B), SP-C analog (derived from an N-terminal segment of SP-C and a helical C-terminal segtment), and the phospholipids dipalmitoyl-phosphatidylcholine and palmitoyl-oleoyl-phosphoglycerol

Networked: 14 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Speer, Christian P: 5 articles (12/2022 - 01/2016)
2.	Salomone, Fabrizio: 4 articles (06/2022 - 01/2017)
3.	Curstedt, Tore: 4 articles (01/2021 - 01/2014)
4.	Fabbri, Laura: 3 articles (12/2022 - 11/2017)
5.	Piccinno, Annalisa: 3 articles (12/2022 - 11/2017)
6.	Santoro, Debora: 3 articles (12/2022 - 11/2017)
7.	Varoli, Guido: 3 articles (12/2022 - 11/2017)
8.	Murgia, Xabier: 3 articles (06/2022 - 01/2017)
9.	Fehrholz, Markus: 3 articles (01/2017 - 01/2016)
10.	Glaser, Kirsten: 3 articles (01/2017 - 01/2016)

Related Diseases

1.	Newborn Respiratory Distress Syndrome 01/01/2023 - "CHF5633, one of the most promising synthetic surfactants, is effective in neonatal respiratory distress syndrome. " 10/01/2020 - "Synthetic Surfactant CHF5633 Compared with Poractant Alfa in the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial."
2.	Lung Injury 01/01/2023 - "CHF5633 improved survival and alleviated meconium-induced lung injury, the same as Poractant alfa. " 01/01/2023 - "Efficacy of synthetic surfactant (CHF5633) bolus and/or lavage in meconium-induced lung injury in ventilated newborn rabbits." 01/01/2023 - "Similar effects on improving survival and alleviating lung injury were found between CHF5633 and Poractant alfa. " 01/01/2023 - "CHF5633 had similar benefits in improving survival and alleviating lung injury as Poractant alfa. " 01/01/2023 - "To explore the efficacy of a synthetic surfactant, CHF5633, in neonatal lung protection comparing with Poractant alfa in a near-term newborn rabbit model with meconium-induced lung injury. "
3.	Brain Injuries (Brain Injury) 01/01/2017 - "Lambs administered CHF5633 obtained better lung and brain injury scores than controls. " 01/01/2017 - "Intratracheal administration of a bolus of CHF5633 improves pulmonary status in preterm lambs with severe RDS, obtaining better lung and brain injury scores than controls and favorable cerebral hemodynamics, comparable to those with gold standard Curosurf treatment."
4.	Inflammation (Inflammations) 01/01/2016 - "Neither CHF5633 nor any of its components induced inflammation or apoptosis in native adult CD14+ monocytes. " 01/01/2021 - "This study indicates that single dose of CHF5633 improves lung function and attenuates inflammation as effectively as poractant alfa in experimental ARDS caused by injurious ventilation." 01/01/2017 - "CHF5633 did not induce pro-inflammation, and did not aggravate Ureaplasma-induced pro-inflammatory cytokine responses. " 10/01/2016 - "CHF5633 did not induce pro-inflammation in native human neonatal monocytes and did not aggravate LPS-induced cytokine responses. " 01/01/2021 - "Impact of synthetic surfactant CHF5633 with SP-B and SP-C analogues on lung function and inflammation in rabbit model of acute respiratory distress syndrome."
5.	Meconium Aspiration Syndrome 01/01/2014 - "This study indicates that CHF5633 is as efficient as poractant alfa in experimental meconium aspiration syndrome."

Related Drugs and Biologics

1.	poractant alfa (Curosurf)
2.	Surface-Active Agents (Surfactants)
3.	Cytokines
4.	Messenger RNA (mRNA)
5.	Pulmonary Surfactants (Pulmonary Surfactant)
6.	Proteins (Proteins, Gene)
7.	Phospholipids (Phosphatides)
8.	Oxygen (Dioxygen)
9.	C-Peptide
10.	Blood Proteins (Serum Proteins)

Related Therapies and Procedures

1.	Therapeutics